PLOS Glob Public Health 4(12): e0004035. https://doi. org/10.1371/journal.pgph.0004035. A new formulation of praziquantel, arpraziquantel (arPZQ), has been developed for preschool- aged children (PSAC) to fill the treatment gap for this age group in schistosomiasis control and elimination programs. There is now a priority to ensure that the drug reaches all at-risk PSAC in endemic areas, including hard-to-reach areas and populations. This study aimed to deter- mine schistosomiasis treatment-related contextual factors among fishermen and island popu- lations in Homa Bay County, Kenya, and to identify a suitable platform to deliver arPZQ.